The reflection of foreign data on nicorandil-induced ulcerations in Russian publications in 2009-2018 years

Bel'diev S.N.
PhD, Associate Professor, Chair for therapy and cardiology¹

Egorova I. V.
PhD, Assistant, Chair for therapy and cardiology¹

Gavrilenko N. G.
PhD, Associate Professor, Chair for foreign and Latin languages¹

Berezina E. I.
PhD, Associate Professor, Chair for therapy and cardiology¹

Medvedeva I. V.
PhD, Associate Professor, Chair for therapy and cardiology¹

Platonov D. Yu.
MD, Head, Chair for therapy and cardiology¹

1 - Tver State Medical University, Tver, Russia

Bel'diev Sergej; e-mail: sbeldiev@yandex.ru

Authors have no conflict of interest.

The study had no sponsorship.

Since 1997 many clinical cases have been described in foreign literature indicating that the antianginal drug nicorandil can cause gastrointestinal (GI) ulcerations, as well as ulcerations outside the GI tract. Relatively recently data have been presented that in a randomized, double-blind, placebo-controlled IONA trial (Impact of Nicorandil in Angina), the main results of which had been published in 2002, nicorandil had significantly increased the risk of GI ulcerations. The paper discusses in detailed examples how these foreign data are presented in Russian publications.

nicorandil, ulceration, translation equivalence

10.29234/2308-9113-2019-7-2-40-58

1. Pisano U., Deosaran J., Leslie S.J., Rushworth G.F., Stewart D., Ford I., et al. Nicorandil, gastrointestinal adverse drug reactions and ulcerations: a systematic review. Adv Ther 2016 Mar; 33(3): 320-44. doi: 10.1007/s12325-016-0294-9. Epub 2016 Feb 9.

2. Babic V., Petitpain N., Guy C., Trechot P., Bursztejn A.C., Faillie J.L., et al. Nicorandil-induced ulcerations: a 10-year observational study of all cases spontaneously reported to the French pharmacovigilance network. Int Wound J 2018; 15(4): 508-18. doi: 10.1111/iwj.12845.

3. Horinaka S. Use of nicorandil in cardiovascular disease and its optimization. Drugs 2011; 71(9): 1105-19. doi: 10.2165/11592300-000000000-00000.

4. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359(9314): 1269-75. doi: 10.1016/s1062-1458(02)00678-5.

5. Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38): 2949-3003. doi: 10.1093/eurheartj/eht296.

6. Nifontov E.M., Andreev Ja.V. Primenenie otkryvatelja ATF-zavisimyh kalievyh kanalov nikorandila dlja lechenija ishemicheskoj bolezni serdca [The application of ATP-sensitive potassium channels' opener nicorandil in treatment of coronary heart disease]. Rossijskij semejnyj vrach [Russian Family Doctor] 2014; 18(3): 18-22. (In Russ.)

7. Lupanov V.P. Primenenie nikorandila – aktivatora kalievyh kanalov – v lechenii bol'nyh s ishemicheskoj bolezn'ju serdca [The use of nicorandil – an activator of potassium channels – in the treatment of patients with ischemic heart disease]. Spravochnik poliklinicheskogo vracha [Directory of polyclinic doctor] 2011; (8): 44-8. (In Russ)

8. Lupanov V.P. Sovremennoe medikamentoznoe lechenie hronicheskoj stabil'noj stenokardii (obzor) [Modern drug therapy of the chronic stable angina (review)]. Medicinskij sovet [Medical Council] 2017; (12): 68-74. (In Russ)

9. Minushkina L.O., Iosava I.K., Sidorenko B.A. Nikorandil v lechenii bol'nyh so stabil'noj ishemicheskoj bolezn'ju serdca [Nicorandil in the treatment of patients with stable ischemic heart disease]. Kremlevskaja medicina. Klinicheskij vestnik [Kremlin medicine. Clinical bulletin] 2017; (1): 114-9. (In Russ)

10. Lupanov V.P. Sovremennoe medikamentoznoe lechenie stabil'noj ishemicheskoj bolezni serdca [Modern medical treatment of stable ischemic heart disease]. RMJ [Russian Medical Journal] 2013; 21(4): 170-4. (In Russ)

11. Reichert S., Antunes A., Trechot P., Barbaud A., Weber M., Schmutz J.-L. Major aphthous stomatitis induced by nicorandil. Eur J Dermatol 1997; 7(2): 132-3.

12. Volkov E.A., Butova V.G., Pozdnyakova T.I., Dzugaeva I.I. Klinicheskie rekomendacii (protokol lechenija) pri hronicheskom recidivirujushhem aftoznom stomatite [Clinical recommendations (treatment protocol) for chronic recurrent aphthous stomatitis]. Rossijskij stomatologicheskij zhurnal [Russian Journal of Dentistry] 2014; (5): 35-49. (In Russ.)

13. Agbo-Godeau S., Joly P., Lauret P., Szpirglas R., Szpirglas H. Association of major aphthous ulcers and nicorandil. Lancet 1998; 352(9140): 1598-9. doi: 10.1016/S0140-6736(05)61045-8.

14. Desruelles F., Bahadoran P., Lacour J.P., Perrin C., Santini J., Ortonne J.P. Giant oral aphthous ulcers induced by nicorandil. Br J Dermatol 1998; 138(4): 712-3. doi: 10.1046/j.1365-2133.1998.02198.x.

15. Gupta A., Morris G. Major aphthous ulcers induced by nicorandil. Age Ageing 2000; 29(4): 372-3. doi: 10.1093/ageing/29.4.372.

16. Boulinguez S., Sommet A., Bédane C., Viraben R., Bonnetblanc J.M. Oral nicorandil-induced lesions are not aphthous ulcers. J Oral Pathol Med 2003; 32(8): 482-5. doi: 10.1034/j.1600-0714.2003.00166.x.

17. Healy C.M., Smyth Y., Flint S.R. Persistent nicorandil induced oral ulceration. Heart 2004; 90(7): e38. doi: 10.1136/hrt.2003.031831.

18. Council for International Organizations of Medical Sciences. Current challenges in pharmacovigilance: pragmatic approaches. Report of CIOMS Working Group V. Geneva, 2001; 381 p.

19. Dunn N., Freemantle S., Pearce G., Wilton L.V., Mann R.D. Safety profile of nicorandil – prescription-event monitoring (PEM) study. Pharmacoepidemiol Drug Saf 1999; 8(3): 197-205. doi: 10.1002/(SICI)1099-1557(199905/06)8:3<197::AID-PDS422>3.0.CO;2-T.

20. Colvin H.S., Barakat T., Moussa O., Babu H., Slaughter T., Palmer J.G., et al. Nicorandil associated anal ulcers: an estimate of incidence. Ann R Coll Surg Engl 2012; 94(3): 170-2. doi: 10.1308/003588412X13171221501573.

21. Claeys A., Weber-Muller F., Trechot P., Cuny J.F., Georges M.Y., Barbaud A., et al. Cutaneous, perivulvar and perianal ulcerations induced by nicorandil. Br J Dermatol 2006; 155(2): 494-6. doi: 10.1111/j.1365-2133.2006.07363.x.

22. Jennesseaux I., Carre-Gislard D., Bravard P. Nicorandil-induced cutaneous ulceration on a pacemaker implantation wound. Ann Dermatol Venereol 2008; 135(2): 131-3. doi: 10.1016/j.annder.2007.06.008. (In French)

23. Abdelrazeq A.S., Owen C., Smith L., McAdam J.G., Pearson H.J., Leveson S.H. Nicorandil-associated para-stomal ulceration: case series. Eur J Gastroenterol Hepatol 2006; 18(12): 1293-5. doi: 10.1097/01.meg.0000243880.02197.8b.

24. Birnie A., Dearing N., Littlewood S., Carlin E. Nicorandil-induced ulceration of the penis. Clin Exp Dermatol 2008; 33(2): 215-6. doi: 10.1111/j.1365-2230.2007.02650.x.

25. McKenna D.J., Donnelly J., Armstrong D.K. Nicorandil-induced leg ulceration. Br J Dermatol 2007; 156(2): 394-6. doi: 10.1111/j.1365-2133.2006.07643.x.

26. Trechot P., Bazard M.C., Petitpain N., Trechot F., Javot L., Angioi K. Conjunctival and corneal ulcerations: keep a sharp eye on nicorandil. Br J Ophthalmol 2012; 96(3): 463-4. doi: 10.1136/bjophthalmol-2011-301302.

27. King P.M., Suttie S.A., Jansen J.O., Watson A.J. Perforation of the terminal ileum: a possible complication of nicorandil therapy. Surgeon 2004; 2(1): 56-7. doi: 10.1016/s1479-666x(04)80140-9.

28. Ogden S., Mukasa Y., Lyon C.C., Coulson I.H. Nicorandil-induced peristomal ulcers: is nicorandil also associated with gastrointestinal fistula formation? Br J Dermatol 2007; 156(3): 608-9. doi: 10.1111/j.1365-2133.2006.07698.x.

29. Kamath S., Kembrey K., Bhagwandas K. Perianal fistula, colorectal surgery and nicorandil. Clin Exp Dermatol 2008; 33(2): 192-3. doi: 10.1111/j.1365-2230.2007.02548.x.

30. Williams C., Tamuno P., Smith A.J., Walker S.L., Lyon C.C. Perianal ulceration and other cutaneous ulcerations complicating nicorandil therapy. J Am Acad Dermatol 2007; 56: 116-7. doi: 10.1016/j.jaad.2006.05.034.

31. Martsevich S.Yu., Kutishenko N.P., Tolpygina S.N., Lukina Ju.V., Koncevaja A.V., Lishuta A.S., et al. Jeffektivnost' i bezopasnost' lekarstvennoj terapii pri pervichnoj i vtorichnoj profilaktike serdechno-sosudistyh zabolevanij [Efficacy and safety of drug therapy for primary and secondary prevention of cardiovascular disease]. Racional'naja farmakoterapija v kardiologii [Rational Pharmacotherapy in Cardiology] 2011; 7(5): 2-72. (In Russ.)

32. Gilyarevskiy S.R., Orlov V.A., Kuz'mina I.M. Problema vybora optimal'noj lekarstvennoj terapii u bol'nyh so stabil'nym techeniem ishemicheskoj bolezni serdca [The problem of the optimal pharmacotherapy choice in patients with stable coronary artery disease]. Racional'naja farmakoterapija v kardiologii [Rational Pharmacotherapy in Cardiology] 2012; 8(3): 457-62. doi: 10.20996/1819-6446-2012-8-3-457-462. (In Russ.)

33. Gilyarevskiy S.R., Rezvan V.V., Kuz'mina I.M., Golshmid M.V. The role of alternative approaches to anti-ischemic therapy in patients with stable course of ischemic heart disease. Kardiologiia [Cardiology] 2013; (11): 84-9. (In Russ.)

34. Gilyarevskiy S.R., Rezvan V.V., Kuz'mina I.M., Golshmid M.V. Sovremennye podhody k protivoishemicheskoj terapii u bol'nyh so stabil'nym techeniem ishemicheskoj bolezni serdca [The modern approaches to anti-ischemic therapy in patients with stable course of ischemic heart disease]. Medicinskij alfavit [Medical Alphabet] 2013; 2(21): 15-20. (In Russ.)

35. Belousov Ju.B. Primenenie nikorandila pri serdechno-sosudistyh zabolevanijah i optimizacija shem ego naznachenija [The use of nicorandil in cardiovascular diseases and the optimization of schemes of its administration]. Arhiv vnutrennej mediciny [The Russian Archives of Internal Medicine] 2012; (1): 46-52. doi: 10.20514/2226-6704-2012-0-1-46-52. (In Russ.)

36. Minushkina L.O., Sidorenko B.A. Nikorandil v lechenii bol'nyh ishemicheskoj bolezn'ju serdca [Nicorandil in the treatment of patients with ischemic heart disease]. Kardiologija [Cardiology] 2013; 53(5): 69-73. (In Russ.)

37. Malysheva A.M., Martsevich S.Ju., Ginzburg M.L. Primenenie nikorandila – preparata s dopolnitel'nymi kardioprotektivnymi svojstvami – u pacientov s ishemicheskoj bolezn'ju serdca [Cardioprotective drug nicorandil in coronary heart disease]. Terapevticheskij arhiv [Therapeutic Archive] 2011; 83(9): 14-9. (In Russ.)

38. Nadlezhashhaja klinicheskaja praktika. Nacional'nyj standart Rossijskoj Federacii GOST R 52379-2005 [Good clinical practice. Russian national standard GOST R 52379-2005]. M.: Standartinform, 2006; 39 p. (In Russ.)

39. Lukina Yu.V., Dmitrieva N.A., Zakharova A.V., Zagrebelnyy A.V., Kutishenko N.P., Martsevich S.Ju. Nezhelatel'nye javlenija lekarstvennoj terapii (pervye rezul'taty issledovanija po dannym ambulatornogo registra PROFIL') [Adverse event of drug therapy (the first results of the study according to the PROFILE outpatient register)]. Racional'naja farmakoterapija v kardiologii [Rational Pharmacotherapy in Cardiology] 2016; 12(3): 306-13. doi: 10.20996/1819-6446-2016-12-3-306-313. (In Russ.)

40. IONA Study Group. Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management. Heart 2001; 85(6): E9. doi: 10.1136/heart.85.6.e9.

41. National Clinical Guidelines Centre (UK). Stable angina: methods, evidence & guidance (NICE Clinical Guidelines, No. 126). London: Royal College of Physicians (UK), 2011; 468 p.

42. Markham A., Plosker G.L., Goa K.L. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000; 60(4): 955-74. doi: 10.2165/00003495-200060040-00007.

43. Simpson D., Wellington K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs 2004; 64(17): 1941-55. doi: 10.2165/00003495-200464170-00012.

44. Gosudarstvennyj reestr lekarstvennyh sredstv. Instrukcija po medicinskomu primeneniju preparata Kordinik (nikorandil) [State Register of Medicines (Russian Federation). Instructions for medical use of the drug Kordinik (nicorandil)]. URL: https://grls.rosminzdrav.ru/Grls­_View­_v2.aspx?routingGuid=eb3d2d96-e1e8-4c3d-9fb4-0936e2b75829&t= Accessed: 03/20/2019. (In Russ.)

45. Fox K., Garcia M.A., Ardissino D., Buszman P., Camici P.G., Crea F., et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27(11): 1341-81. doi: 10.1093/eurheartj/ehl001.

46. Rekomendacii po lecheniju stabil'noj ishemicheskoj bolezni serdca. ESC 2013 [2013 ESC guidelines on the management of stable coronary artery disease]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology] 2014; (7): 7-79. doi: 10.15829/1560-4071-2014-7-7-79. (In Russ.)

47. Fox K., Garcia M., Ardissimo D., Buszman P., Camici P., Crea F. et al. Rekomendacii po vedeniju bol'nyh stabil'noj stenokardiej [Guidelines on the management of stable angina pectoris]. Racional'naja farmakoterapija v kardiologii [Rational Pharmacotherapy in Cardiology] 2007; 3(1): 69-100. doi: 10.20996/1819-6446-2007-3-1-69-100. (In Russ.)

48. Mironov V.A., Mironova T.F., Pavlova I.V., Kuvatova E.V. Rekomendacii Evropejskogo obshhestva kardiologov po diagnostike i lecheniju stabil'noj stenokardii naprjazhenija (2013) Adaptirovannyj perevod. [European Society of Cardiology guidelines on the diagnosis and treatment of stable angina pectoris (2013). Adapted translation]. Vestnik Cheljabinskoj oblastnoj klinicheskoj bol'nicy [Bulletin of Chelyabinsk regional clinical hospital] 2014; 26(3): 85-95. (In Russ.)

49. Lupanov V.P. Novye Evropejskie metodicheskie rekomendacii 2013 g. po lecheniju stabil'noj ishemicheskoj bolezni serdca [New European guidelines 2013 on the treatment of stable ischemic heart disease]. RMZh [Russian Medical Journal] 2014; 22(2): 98-105. (In Russ.)

50. Petrova E.D., Platonova M.D., Bel'diev S.N., Egorova I.V. Opisanie ul'cerogennyh jeffektov nikorandila v evropejskoj i otechestvennoj instrukcijah po medicinskomu primeneniju preparata [Description of nicorandil-induced ulceration in European and Russian instructions for the medical use of the drug]. Molodezh' i medicinskaja nauka: stat'i VI Vserossijskoj mezhvuzovskoj nauchno-prakticheskoj konferencii molodyh uchenyh s mezhdunarodnym uchastiem (Tver', 22 sentjabrja 2018 g.) [Youth and medical science: articles of VI Russian inter-university scientific and practical conference of young scientists with international participation (Tver, September 22, 2018)]. Tver', 2019. P. 314-17. (In Russ.)